Nasal Polyps clinical trials at UC Irvine
1 research study open to eligible people
Showing trials for
Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
open to eligible people ages 18 years and up
The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with chronic rhinosinusitis and nasal polyps treated with intranasal corticosteroids. The study will last about 18 months.
Irvine 5359777, California 5332921 and other locations
Our lead scientists for Nasal Polyps research studies include Naveen Bhandarkar.
Last updated: